National Cancer Centre Singapore (NCCS) is currently conducting an extensive portfolio of 40 clinical trials, representing one of the most comprehensive cancer research programs in Southeast Asia. The trials span multiple cancer types and treatment modalities, offering patients access to innovative therapies while advancing the global understanding of cancer treatment.
Breakthrough Therapies in Genitourinary Cancers
The center is leading several pivotal studies in bladder and prostate cancers. The SGNV-001 trial (NCT05911295) represents a significant advancement in HER2-positive urothelial carcinoma treatment, comparing disitamab vedotin combined with pembrolizumab against standard chemotherapy in previously untreated patients with locally advanced or metastatic disease. This Phase III randomized controlled study, led by Dr. Ravindran Kanesvaran, targets tumors expressing HER2 at IHC 1+ levels and greater.
Another notable genitourinary study is the BT8009-230 trial (NCT06225596), the Duravelo-2 study examining BT8009 as monotherapy or in combination for locally advanced or metastatic urothelial cancer. Dr. Tan Wei Chong serves as the principal investigator for this randomized open-label Phase 2/3 study.
In prostate cancer, the AMG 20230005 trial (NCT06691984) is evaluating xaluritamig versus cabazitaxel or second androgen receptor-directed therapy in patients with progressive metastatic castration-resistant prostate cancer, under the leadership of Dr. Johan Chan.
Comprehensive Breast Cancer Research Program
NCCS is conducting nine active breast cancer trials covering various subtypes and treatment stages. The TROPION-Breast04 study (NCT06112379), led by Dr. Rebecca Dent, represents a major Phase III investigation comparing neoadjuvant datopotamab deruxtecan plus durvalumab against pembrolizumab plus chemotherapy in triple-negative or HR-low/HER2-negative breast cancer patients.
For HER2-positive metastatic breast cancer with PIK3CA mutations, the INAVO122 trial (NCT05894239) is evaluating inavolisib in combination with Phesgo versus placebo, conducted under Dr. Yap Yoon Sim's supervision. This Phase III, multicenter, randomized, double-blind, placebo-controlled study focuses on patients who have received first-line induction therapy.
The ELEVATE trial (NCT05181033) addresses endocrine-resistant disease by comparing letrozole and lenvatinib versus fulvestrant in metastatic estrogen receptor-positive, HER2-negative breast cancer patients who have progressed on CDK4/6 inhibitors.
Advanced Lung Cancer Treatment Innovations
The lung cancer program encompasses 11 trials addressing both non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). The BEAMION LUNG-02 study (NCT06151574) represents a significant advancement in HER2-mutated NSCLC treatment, evaluating orally administered BI 1810631 compared with standard of care as first-line treatment in patients with unresectable, locally advanced, or metastatic non-squamous NSCLC harboring HER2 tyrosine kinase domain mutations.
For limited-stage small-cell lung cancer, the DeLLphi-306 trial (NCT06117774) is investigating tarlatamab therapy in patients who have not progressed following concurrent chemoradiation therapy. This Phase 3, randomized, double-blind, placebo-controlled study is led by Dr. Amit Jain.
The REZILIENT3 trial (NCT05973773) addresses a challenging patient population with EGFR exon 20 insertion mutations, comparing zipalertinib plus chemotherapy versus chemotherapy alone in previously untreated, locally advanced or metastatic nonsquamous NSCLC patients.
Innovative Approaches in Hematologic Malignancies
The lymphoma research program includes five active trials exploring novel therapeutic combinations. The OLYMPIA-4 study (NCT06230224) is evaluating odronextamab, an anti-CD20 x anti-CD3 bispecific antibody, versus standard of care therapy in participants with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
The POLAR trial (NCT06160843) represents an innovative approach combining pembrolizumab and olaparib for relapsed or refractory peripheral T-cell lymphoma, led by Dr. Lim Soon Thye.
Gastrointestinal Cancer Research Excellence
NCCS is conducting multiple trials in hepatocellular carcinoma, gastric cancer, and pancreatic cancer. The AHCC09 trial (NCT05377034) compares selective internal radiation therapy followed by atezolizumab plus bevacizumab versus SIRT-Y90 followed by placebo in patients with locally advanced hepatocellular carcinoma.
For gastric and gastroesophageal junction adenocarcinoma, the ASPEN-06 study (NCT05002127) is investigating ALX148 in patients with advanced HER2-overexpressing tumors, though this trial is currently on hold.
Emerging Technologies and Personalized Medicine
Several trials incorporate cutting-edge technologies including tumor treating fields, CAR-T cell therapy, and personalized neoantigen vaccines. The LUNAR-2 EF-44 trial (NCT06216301) is evaluating tumor treating fields at 150 kHz concomitant with pembrolizumab and platinum-based chemotherapy for metastatic NSCLC.
The CA209-7R9 study (NCT04912765) represents a pioneering approach using neoantigen dendritic cell vaccines combined with nivolumab as adjuvant treatment in resected hepatocellular carcinoma and liver metastases from colorectal cancer.
Clinical Impact and Future Directions
This comprehensive trial portfolio demonstrates NCCS's commitment to advancing cancer care through rigorous clinical research. The studies encompass various phases from early-phase dose-finding studies to pivotal Phase III trials that could reshape treatment standards. The inclusion of biomarker-driven trials and personalized medicine approaches reflects the center's focus on precision oncology.
The trials are investigating multiple therapeutic modalities including antibody-drug conjugates, bispecific antibodies, immune checkpoint inhibitors, targeted therapies, and novel combination regimens. This diverse approach ensures that patients across different cancer types and stages have access to potentially life-changing experimental treatments while contributing to the global advancement of cancer therapeutics.
